FILTER
LATEST INTERVIEWS
Alfred Baku
EXECUTIVE VP AND HEAD OF WEST AFRICA, GOLD FIELDS
Gold Fields updats GBR on its Ghanaian assets.
Sébastien de Montessus
PRESIDENT & CEO, ENDEAVOUR MINING
Endeavour Mining explains its production and exploration activities as the largest gold producer in West Africa.
Dean McPherson
HEAD, BUSINESS DEVELOPMENT – GLOBAL MINING, TORONTO STOCK EXCHANGE AND TSX VENTURE EXCHANGE
The Toronto Stock Exchange and TSXV explains how new and different investors are being attracted to mining and how the exchange supports growth.
Ewan Downie
CEO, I-80 GOLD CORP
i-80 Gold Corp. is a gold producer and developer with a wide portfolio of advanced-stage gold projects in Nevada.
Keith Jones
GENERAL MANAGER, SMALL MINE DEVELOPMENT
Small Mine Development explains its service offering and gives insights about new mining methods.
Chris Hodgson
PRESIDENT, ONTARIO MINING ASSOCIATION (OMA)
The Ontario Mining Association explains how safety and ESG are ensured in mines across the province.
German Torres
REGIONAL PRESIDENT, BRENNTAG ESSENTIALS LATIN AMERICA
Brenntag explains the role of the chemical distribution segment in Latin America.
Steven Poulton
CEO, ALTUS STRATEGIES
Altus Strategies explains its particular royalty generator model that is primarily focused on Africa.
Franco Pedraz
COUNTRY MANAGER – PERU, WORLEY
Worley speaks to GBR in Peru about how its sustainable solutions for mining are being deployed.
Gabriel Rodríguez Garrido
EXECUTIVE DIRECTOR, ARGENTINE PETROCHEMICAL INSTITUTE (IPA)
The Argentine Petrochemical Institute (IPA) explains how it supports Argentina’s petrochemical industry.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
